肥胖型PCOS患者的生物学特征和临床特征

doi:10.12280/gjszjk.20220067

摘要/Abstract

摘要：

多囊卵巢综合征（polycystic ovary syndrome,PCOS）是一种内分泌代谢紊乱综合征,临床表现高度异质性。肥胖是PCOS异质性临床表现之一,超过50%的PCOS患者超重或肥胖。肥胖型PCOS主要表现为高雄激素血症、中心型肥胖和糖脂代谢紊乱,非肥胖型PCOS主要表现为黄体生成激素（luteinizing hormone,LH）水平异常升高。尽管肥胖型和非肥胖型PCOS均存在内分泌代谢异常,然而肥胖可加重PCOS糖脂代谢紊乱;肥胖型PCOS还表现脂肪代谢的异常。综述肥胖型PCOS患者的临床特征、性激素水平、糖脂代谢特征,旨在为肥胖型和非肥胖型PCOS患者新的分型诊治提供参考。

关键词: 多囊卵巢综合征, 肥胖症, 性腺甾类激素, 葡萄糖代谢障碍, 脂代谢障碍

Abstract:

Polycystic ovary syndrome (PCOS) is an endocrine and metabolic syndrome with highly heterogeneous manifestations. Obesity is one of the heterogeneous manifestations of PCOS, and more than 50% of PCOS patients are overweight or obese. Obese PCOS is characterized mainly by hyperandrogenism, central obesity and disturbed glucose and lipid metabolism, while non-obese PCOS is characterized mainly by abnormally elevated level of luteinizing hormone (LH). Although the endocrine metabolic abnormalities are present in both obese and non-obese PCOS, obesity exacerbates the disturbed glycolipid metabolism in PCOS patients. The obese PCOS also expresses the abnormality of lipid metabolism. In this review, we summarizethe clinical features, sex hormone levels and glycolipid metabolism of obese PCOS patients, so as to provide a reference for the new diagnosis and treatment of obese and non obese patients with PCOS.

Key words: Polycystic ovary syndrome, Obesity, Gonadal steroid hormones, Glucose metabolism disorders, Lipid metabolism disorders

王娇剑, 鲁娣, 陈然然, 宋殿荣. 肥胖型PCOS患者的生物学特征和临床特征[J]. 国际生殖健康/计划生育, 2022, 41(3): 230-235.

WANG Jiao-jian, LU Di, CHEN Ran-ran, SONG Dian-rong. Biological and Clinical Characteristics of Obese PCOS Patients[J]. Journal of International Reproductive Health/Family Planning, 2022, 41(3): 230-235.

参考文献 35

[1]	Dumesic DA, Oberfield SE, Stener-Victorin E, et al. Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome[J]. Endocr Rev, 2015, 36(5):487-525. doi: 10.1210/er.2015-1018. doi: 10.1210/er.2015-1018 pmid: 26426951
[2]	Zeng X, Xie YJ, Liu YT, et al. Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity[J]. Clin Chim Acta, 2020, 502:214-221. doi: 10.1016/j.cca.2019.11.003. doi: S0009-8981(19)32118-7 pmid: 31733195
[3]	Li R, Zhang Q, Yang D, et al. Prevalence of polycystic ovary syndrome in women in China: a large community-based study[J]. Hum Reprod, 2013, 28(9):2562-2569. doi: 10.1093/humrep/det262. doi: 10.1093/humrep/det262 URL
[4]	Dapas M, Lin FTJ, Nadkarni GN, et al. Distinct subtypes of polycystic ovary syndrome with novel genetic associations: An unsupervised, phenotypic clustering analysis[J]. PLoS Med, 2020, 17(6):e1003132. doi: 10.1371/journal.pmed.1003132. doi: 10.1371/journal.pmed.1003132 URL
[5]	Zhang HY, Guo CX, Zhu FF, et al. Clinical characteristics,metabolic features,and phenotype of Chinese women with polycystic ovary syndrome: a large-scale case-control study[J]. Arch Gynecol Obstet, 2013, 287(3):525-531. doi: 10.1007/s00404-012-2568-z. doi: 10.1007/s00404-012-2568-z pmid: 23108387
[6]	杨艳婷, 侯丽辉, 孙淼. 不同体质量指数对多囊卵巢综合征伴高雄激素血症患者临床体征及内分泌代谢指标影响[J]. 辽宁中医药大学学报, 2020, 22(1):154-157. doi: 10.13194/j.issn.1673-842x. 2020.01.042. doi: 10.13194/j.issn.1673-842x. 2020.01.042
[7]	于婧璐, 侯丽辉, 孙淼, 等. 不同体重指数的多囊卵巢综合征患者的临床特征差异性分析[J]. 中国医药导报, 2020, 17(26):75-78.
[8]	Mu L, Zhao Y, Li R, et al. Metabolic characteristics of normal weight central obesity phenotype polycystic ovary syndrome women: a large-scale national epidemiological survey[J]. Reprod Biomed Online, 2018, 37(4):498-504. doi: 10.1016/j.rbmo.2018.08.007. doi: 10.1016/j.rbmo.2018.08.007 URL
[9]	Satyaraddi A, Cherian KE, Kapoor N, et al. Body Composition, Metabolic Characteristics, and Insulin Resistance in Obese and Nonobese Women with Polycystic Ovary Syndrome[J]. J Hum Reprod Sci, 2019, 12(2):78-84. doi: 10.4103/jhrs.JHRS_2_19. doi: 10.4103/jhrs.JHRS_2_19 pmid: 31293320
[10]	Dumesic DA, Tulberg A, Leung KL, et al. Accelerated subcutaneous abdominal stem cell adipogenesis predicts insulin sensitivity in normal-weight women with polycystic ovary syndrome[J]. Fertil Steril, 2021, 116(1):232-242. doi: 10.1016/j.fertnstert.2020.10.003. doi: 10.1016/j.fertnstert.2020.10.003 URL
[11]	Seth MK, Gulati S, Gulati S, et al. "Association of Leptin with Polycystic Ovary Syndrome: a Systematic Review and Meta-Analysis"[J]. J Obstet Gynaecol India, 2021, 71(6):567-576. doi: 10.1007/s13224-021-01510-0. doi: 10.1007/s13224-021-01510-0 URL
[12]	de Medeiros SF, Rodgers RJ, Norman RJ. Adipocyte and steroidogenic cell cross-talk in polycystic ovary syndrome[J]. Hum Reprod Update, 2021, 27(4):771-796. doi: 10.1093/humupd/dmab004. doi: 10.1093/humupd/dmab004 URL
[13]	Alatas SE, Yavuz DS, Kilic D, et al. Comparison of serum adiponectin and osteopontin levels along with metabolic risk factors between obese and lean women with and without PCOS[J]. Endokrynol Pol, 2020, 71(6):497-503. doi: 10.5603/EP.a2020.0074. doi: 10.5603/EP.a2020.0074 URL
[14]	Bannigida DM, Nayak SB, R V. Serum visfatin and adiponectin - markers in women with polycystic ovarian syndrome[J]. Arch Physiol Biochem, 2020, 126(4):283-286. doi: 10.1080/13813455.2018. 1518987. doi: 10.1080/13813455.2018.1518987 pmid: 30318936
[15]	Taylor AE, McCourt B, Martin KA, et al. Determinants of Abnormal Gonadotropin Secretion in Clinically Defined Women with Polycystic Ovary Syndrome[J]. J Clin Endocrinol Metab, 1997, 82(7):2248-2256. doi: 10.1210/jcem.82.7.4105. doi: 10.1210/jcem.82.7.4105
[16]	Lin K, Sun X, Wang X, et al. Circulating Adipokine Levels in Nonobese Women With Polycystic Ovary Syndrome and in Nonobese Control Women: A Systematic Review and Meta-Analysis[J]. Front Endocrinol(Lausanne), 2021, 11:537809. doi: 10.3389/fendo.2020.537809. doi: 10.3389/fendo.2020.537809
[17]	Margarit L, Taylor A, Roberts MH, et al. MUC1 as a Discriminator between Endometrium from Fertile and Infertile Patients with PCOS and Endometriosis[J]. J Clin Endocrinol Metab, 2010, 95(12):5320-5329. doi: 10.1210/jc.2010-0603. doi: 10.1210/jc.2010-0603 pmid: 20826587
[18]	Albaghdadi AJH, Kan FWK. Therapeutic Potentials of Low-Dose Tacrolimus for Aberrant Endometrial Features in Polycystic Ovary Syndrome[J]. Int J Mol Sci, 2021, 22(6):2872. doi: 10.3390/ijms22062872. doi: 10.3390/ijms22062872 URL
[19]	Yang H, Di J, Pan J, et al. The Association Between Prolactin and Metabolic Parameters in PCOS Women: A Retrospective Analysis[J]. Front Endocrinol(Lausanne), 2020, 11:263. doi: 10.3389/fendo.2020.00263. doi: 10.3389/fendo.2020.00263
[20]	Yang H, Lin J, Li H, et al. Prolactin Is Associated With Insulin Resistance and Beta-Cell Dysfunction in Infertile Women With Polycystic Ovary Syndrome[J]. Front Endocrinol(Lausanne), 2021, 12:571229. doi: 10.3389/fendo.2021.571229. doi: 10.3389/fendo.2021.571229
[21]	Dietz de Loos A, Hund M, Buck K, et al. Antimüllerian hormone to determine polycystic ovarian morphology[J]. Fertil Steril, 2021, 116(4):1149-1157. doi: 10.1016/j.fertnstert.2021.05.094. doi: 10.1016/j.fertnstert.2021.05.094 URL
[22]	Evliyaoglu O, Imohl M, Weiskirchen R, et al. Age-specific reference values improve the diagnostic performance of AMH in polycystic ovary syndrome[J]. Clin Chem Lab Med, 2020, 58(8):1291-1301. doi: 10.1515/cclm-2019-1059. doi: 10.1515/cclm-2019-1059 pmid: 32069226
[23]	Tata B, Mimouni N, Barbotin AL, et al. Elevated prenatal anti-Mullerian hormone reprograms the fetus and induces polycystic ovary syndrome in adulthood[J]. Nat Med, 2018, 24(6):834-846. doi: 10.1038/s41591-018-0035-5. doi: 10.1038/s41591-018-0035-5 URL
[24]	Zhu S, Zhang B, Jiang X, et al. Metabolic disturbances in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis[J]. Fertil Steril, 2019, 111(1):168-177. doi: 10.1016/j.fertnstert.2018.09.013. doi: 10.1016/j.fertnstert.2018.09.013 URL
[25]	Ryu KJ, Kim MS, Kim HK, et al. Risk of type 2 diabetes is increased in nonobese women with polycystic ovary syndrome: the National Health Insurance Service-National Sample Cohort Study[J]. Fertil Steril, 2021, 115(6):1569-1575. doi: 10.1016/j.fertnstert. 2020.12.018. doi: 10.1016/j.fertnstert.2020.12.018 pmid: 33509630
[26]	Leung KL, Sanchita S, Pham CT, et al. Dynamic changes in chromatin accessibility, altered adipogenic gene expression, and total versus de novo fatty acid synthesis in subcutaneous adipose stem cells of normal-weight polycystic ovary syndrome (PCOS) women during adipogenesis: evidence of cellular programming[J]. Clin Epigenetics, 2020, 12(1):181. doi: 10.1186/s13148-020-00970-x. doi: 10.1186/s13148-020-00970-x URL
[27]	Falcetta P, Benelli E, Molinaro A, et al. Effect of aging on clinical features and metabolic complications of women with polycystic ovary syndrome[J]. J Endocrinol Invest, 2021, 44(12):2725-2733. doi: 10.1007/s40618-021-01594-5. doi: 10.1007/s40618-021-01594-5 pmid: 34089497
[28]	Livadas S, Macut D, Bothou C, et al. Insulin resistance, androgens, and lipids are gradually improved in an age-dependent manner in lean women with polycystic ovary syndrome: insights from a large Caucasian cohort[J]. Hormones(Athens), 2020, 19(4):531-539. doi: 10.1007/s42000-020-00211-z. doi: 10.1007/s42000-020-00211-z
[29]	Reinehr T, Kulle A, Rothermel J, et al. Longitudinal analyses of the steroid metabolome in obese PCOS girls with weight loss[J]. Endocr Connect, 2017, 6(4):213-224. doi: 10.1530/EC-17-0051. doi: 10.1530/EC-17-0051 pmid: 28373267
[30]	周红娣, 王哲蔚. PCOS患者停用复方口服避孕药治疗后无排卵复发的影响因素分析[J]. 中华生殖与避孕杂志, 2021, 41(9):798-804. doi: 10.3760/cma.j.cn101441-20200708-00384. doi: 10.3760/cma.j.cn101441-20200708-00384
[31]	Pkhaladze L, Russo M, Unfer V, et al. Treatment of lean PCOS teenagers: a follow-up comparison between Myo-Inositol and oral contraceptives[J]. Eur Rev Med Pharmacol Sci, 2021, 25(23):7476-7485. doi: 10.26355/eurrev_202112_27447. doi: 10.26355/eurrev_202112_27447
[32]	Kumari AS, Haq A, Jayasundaram R, et al. Metformin monotherapy in lean women with polycystic ovary syndrome[J]. Reprod Biomed Online, 2005, 10(1):100-104. doi: 10.1016/s1472-6483(10)60809-7. doi: 10.1016/s1472-6483(10)60809-7 pmid: 15705302
[33]	Zhou H, Zhang D, Luo Z, et al. Association between Body Mass Index and Reproductive Outcome in Women with Polycystic Ovary Syndrome Receiving IVF/ICSI-ET[J]. Biomed Res Int, 2020, 2020:6434080. doi: 10.1155/2020/6434080. doi: 10.1155/2020/6434080
[34]	Lin J, Huang J, Wang N, et al. Effects of pre-pregnancy body mass index on pregnancy and perinatal outcomes in women with PCOS undergoing frozen embryo transfer[J]. BMC Pregnancy Childbirth, 2019, 19(1):487. doi: 10.1186/s12884-019-2611-1. doi: 10.1186/s12884-019-2611-1 URL
[35]	Oróstica L, Astorga I, Plaza-Parrochia F, et al. Proinflammatory environment and role of TNF-alpha in endometrial function of obese women having polycystic ovarian syndrome[J]. Int J Obes(Lond),2016, 40(11):1715-1722. doi: 10.1038/ijo.2016.154. doi: 10.1038/ijo.2016.154 URL